ORIC Pharmaceuticals, Inc.
ORIC
$5.78
$0.254.52%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 7.60M | 7.12M | 7.08M | 7.03M | 6.95M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 39.57M | 38.32M | 36.02M | 28.99M | 31.43M |
Operating Income | -39.57M | -38.32M | -36.02M | -28.99M | -31.43M |
Income Before Tax | -36.31M | -34.57M | -31.96M | -25.01M | -28.33M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -36.31M | -34.57M | -31.96M | -25.01M | -28.33M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -36.31M | -34.57M | -31.96M | -25.01M | -28.33M |
EBIT | -39.57M | -38.32M | -36.02M | -28.99M | -31.43M |
EBITDA | -39.27M | -38.05M | -35.75M | -28.73M | -31.17M |
EPS Basic | -0.51 | -0.49 | -0.45 | -0.37 | -0.49 |
Normalized Basic EPS | -0.32 | -0.31 | -0.28 | -0.23 | -0.31 |
EPS Diluted | -0.51 | -0.49 | -0.45 | -0.37 | -0.49 |
Normalized Diluted EPS | -0.32 | -0.31 | -0.28 | -0.23 | -0.31 |
Average Basic Shares Outstanding | 70.65M | 70.54M | 70.35M | 67.35M | 57.46M |
Average Diluted Shares Outstanding | 70.65M | 70.54M | 70.35M | 67.35M | 57.46M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |